nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—Cytochrome P450 3A4 Inducers—Topiramate—migraine	0.663	1	CiPCiCtD
Dabrafenib—SLC22A8—Valproic Acid—migraine	0.0319	0.14	CbGbCtD
Dabrafenib—SLCO1B1—Verapamil—migraine	0.0301	0.132	CbGbCtD
Dabrafenib—ABCG2—Verapamil—migraine	0.0239	0.105	CbGbCtD
Dabrafenib—SLC22A6—Valproic Acid—migraine	0.0222	0.0974	CbGbCtD
Dabrafenib—CYP2C8—Amitriptyline—migraine	0.0161	0.0703	CbGbCtD
Dabrafenib—CYP2C8—Valproic Acid—migraine	0.0146	0.0641	CbGbCtD
Dabrafenib—ABCB1—Timolol—migraine	0.0141	0.0618	CbGbCtD
Dabrafenib—CYP2C8—Verapamil—migraine	0.0127	0.0558	CbGbCtD
Dabrafenib—ABCB1—Propranolol—migraine	0.0126	0.0551	CbGbCtD
Dabrafenib—ABCB1—Amitriptyline—migraine	0.0109	0.0476	CbGbCtD
Dabrafenib—ABCB1—Verapamil—migraine	0.00863	0.0378	CbGbCtD
Dabrafenib—CYP3A4—Propranolol—migraine	0.00753	0.033	CbGbCtD
Dabrafenib—CYP3A4—Amitriptyline—migraine	0.00651	0.0285	CbGbCtD
Dabrafenib—CYP3A4—Valproic Acid—migraine	0.00594	0.026	CbGbCtD
Dabrafenib—CYP3A4—Topiramate—migraine	0.00536	0.0235	CbGbCtD
Dabrafenib—CYP3A4—Verapamil—migraine	0.00517	0.0226	CbGbCtD
Dabrafenib—RAF1—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2B—migraine	0.000749	0.031	CbGpPWpGaD
Dabrafenib—RAF1—Endothelin Pathways—CALCRL—migraine	0.000743	0.0307	CbGpPWpGaD
Dabrafenib—RAF1—Endothelin Pathways—RAMP1—migraine	0.000743	0.0307	CbGpPWpGaD
Dabrafenib—SIK1—LKB1 signaling events—ESR1—migraine	0.000689	0.0285	CbGpPWpGaD
Dabrafenib—NEK11—cerebellum—migraine	0.000687	0.0741	CbGeAlD
Dabrafenib—BRAF—Serotonin Receptor 4/6/7 and NR3C Signaling—HTR7—migraine	0.000598	0.0248	CbGpPWpGaD
Dabrafenib—SIK1—trigeminal ganglion—migraine	0.000583	0.0629	CbGeAlD
Dabrafenib—NEK11—brain—migraine	0.000558	0.0602	CbGeAlD
Dabrafenib—RAF1—neck—migraine	0.000537	0.0579	CbGeAlD
Dabrafenib—LIMK1—cerebellum—migraine	0.000492	0.053	CbGeAlD
Dabrafenib—RAF1—trigeminal ganglion—migraine	0.000464	0.05	CbGeAlD
Dabrafenib—RAF1—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2C—migraine	0.000454	0.0188	CbGpPWpGaD
Dabrafenib—RAF1—Stimuli-sensing channels—TRPM8—migraine	0.000441	0.0182	CbGpPWpGaD
Dabrafenib—BRAF—Ras signaling in the CD4+ TCR pathway—FOS—migraine	0.000428	0.0177	CbGpPWpGaD
Dabrafenib—RAF1—brainstem—migraine	0.000411	0.0443	CbGeAlD
Dabrafenib—LIMK1—brain—migraine	0.0004	0.0431	CbGeAlD
Dabrafenib—SIK1—TGF-beta Signaling Pathway—TGFBR2—migraine	0.000389	0.0161	CbGpPWpGaD
Dabrafenib—SIK1—Circadian rythm related genes—NPS—migraine	0.000376	0.0155	CbGpPWpGaD
Dabrafenib—BRAF—B Cell Receptor Signaling Pathway—MEF2D—migraine	0.000369	0.0153	CbGpPWpGaD
Dabrafenib—SIK1—Circadian rythm related genes—SLC6A4—migraine	0.000368	0.0152	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—SCN1A—migraine	0.000362	0.015	CbGpPWpGaD
Dabrafenib—LIMK1—RhoA signaling pathway—FOS—migraine	0.000336	0.0139	CbGpPWpGaD
Dabrafenib—RAF1—cardiovascular system—migraine	0.000335	0.0361	CbGeAlD
Dabrafenib—SIK1—Circadian rythm related genes—HTR7—migraine	0.000323	0.0134	CbGpPWpGaD
Dabrafenib—BRAF—Estrogen signaling pathway—ESR1—migraine	0.000319	0.0132	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—SCN2A—migraine	0.000308	0.0127	CbGpPWpGaD
Dabrafenib—BRAF—cerebellum—migraine	0.000304	0.0328	CbGeAlD
Dabrafenib—BRAF—Neuronal System—KCNK18—migraine	0.000302	0.0125	CbGpPWpGaD
Dabrafenib—RAF1—Ras signaling in the CD4+ TCR pathway—FOS—migraine	0.000296	0.0123	CbGpPWpGaD
Dabrafenib—RAF1—Endothelin Pathways—EDNRA—migraine	0.000296	0.0122	CbGpPWpGaD
Dabrafenib—BRAF—Estrogen signaling pathway—FOS—migraine	0.000288	0.0119	CbGpPWpGaD
Dabrafenib—RAF1—Ion channel transport—TRPM8—migraine	0.000288	0.0119	CbGpPWpGaD
Dabrafenib—SIK1—head—migraine	0.000285	0.0307	CbGeAlD
Dabrafenib—RAF1—Endothelin Pathways—CALCA—migraine	0.000285	0.0118	CbGpPWpGaD
Dabrafenib—RAF1—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—migraine	0.000278	0.0115	CbGpPWpGaD
Dabrafenib—SIK1—nervous system—migraine	0.00027	0.0291	CbGeAlD
Dabrafenib—SLC22A8—trigeminal ganglion—migraine	0.00027	0.0291	CbGeAlD
Dabrafenib—SIK1—central nervous system—migraine	0.00026	0.0281	CbGeAlD
Dabrafenib—RAF1—FSH signaling pathway—BDNF—migraine	0.000259	0.0107	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—SCN1A—migraine	0.000258	0.0107	CbGpPWpGaD
Dabrafenib—RAF1—B Cell Receptor Signaling Pathway—MEF2D—migraine	0.000255	0.0106	CbGpPWpGaD
Dabrafenib—SIK1—cerebellum—migraine	0.000254	0.0274	CbGeAlD
Dabrafenib—SIK1—TGF-beta Signaling Pathway—FOS—migraine	0.000253	0.0105	CbGpPWpGaD
Dabrafenib—RAF1—Extracellular vesicle-mediated signaling in recipient cells—TGFBR2—migraine	0.000247	0.0102	CbGpPWpGaD
Dabrafenib—BRAF—brain—migraine	0.000247	0.0266	CbGeAlD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—MEF2D—migraine	0.000245	0.0101	CbGpPWpGaD
Dabrafenib—RAF1—head—migraine	0.000227	0.0245	CbGeAlD
Dabrafenib—BRAF—PDGFR-beta signaling pathway—LRP1—migraine	0.00022	0.0091	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—SCN2A—migraine	0.00022	0.00909	CbGpPWpGaD
Dabrafenib—RAF1—Ion channel transport—ATP1A3—migraine	0.000218	0.00902	CbGpPWpGaD
Dabrafenib—RAF1—Ion channel transport—ATP1A2—migraine	0.000218	0.00902	CbGpPWpGaD
Dabrafenib—RAF1—nervous system—migraine	0.000215	0.0232	CbGeAlD
Dabrafenib—BRAF—Trk receptor signaling mediated by the MAPK pathway—FOS—migraine	0.00021	0.00871	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—KCNK18—migraine	0.000209	0.00864	CbGpPWpGaD
Dabrafenib—RAF1—central nervous system—migraine	0.000207	0.0223	CbGeAlD
Dabrafenib—SIK1—brain—migraine	0.000207	0.0223	CbGeAlD
Dabrafenib—RAF1—cerebellum—migraine	0.000202	0.0218	CbGeAlD
Dabrafenib—LIMK1—Developmental Biology—MEF2D—migraine	0.000201	0.00831	CbGpPWpGaD
Dabrafenib—BRAF—Transmission across Chemical Synapses—CACNA1A—migraine	0.000192	0.00796	CbGpPWpGaD
Dabrafenib—ABCG2—trigeminal ganglion—migraine	0.000192	0.0207	CbGeAlD
Dabrafenib—RAF1—Ion channel transport—HTR3A—migraine	0.000185	0.00767	CbGpPWpGaD
Dabrafenib—RAF1—Endothelins—EDNRA—migraine	0.000176	0.00729	CbGpPWpGaD
Dabrafenib—Dehydration—Topiramate—migraine	0.000172	0.00228	CcSEcCtD
Dabrafenib—Hypotension—Verapamil—migraine	0.000172	0.00227	CcSEcCtD
Dabrafenib—Epistaxis—Timolol—migraine	0.000172	0.00227	CcSEcCtD
Dabrafenib—Eye disorder—Valproic Acid—migraine	0.000172	0.00227	CcSEcCtD
Dabrafenib—Hyperglycaemia—Gabapentin—migraine	0.000172	0.00227	CcSEcCtD
Dabrafenib—Constipation—Propranolol—migraine	0.000171	0.00226	CcSEcCtD
Dabrafenib—Infestation NOS—Gabapentin—migraine	0.00017	0.00224	CcSEcCtD
Dabrafenib—Infestation—Gabapentin—migraine	0.00017	0.00224	CcSEcCtD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—MEF2D—migraine	0.00017	0.00702	CbGpPWpGaD
Dabrafenib—Abdominal pain upper—Topiramate—migraine	0.000169	0.00224	CcSEcCtD
Dabrafenib—Hypokalaemia—Topiramate—migraine	0.000168	0.00223	CcSEcCtD
Dabrafenib—Diarrhoea—Amitriptyline—migraine	0.000168	0.00222	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Verapamil—migraine	0.000168	0.00222	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Topiramate—migraine	0.000167	0.00221	CcSEcCtD
Dabrafenib—Renal failure—Gabapentin—migraine	0.000167	0.00221	CcSEcCtD
Dabrafenib—Angiopathy—Valproic Acid—migraine	0.000167	0.0022	CcSEcCtD
Dabrafenib—Insomnia—Verapamil—migraine	0.000166	0.0022	CcSEcCtD
Dabrafenib—Immune system disorder—Valproic Acid—migraine	0.000166	0.00219	CcSEcCtD
Dabrafenib—Nasopharyngitis—Topiramate—migraine	0.000166	0.00219	CcSEcCtD
Dabrafenib—Mediastinal disorder—Valproic Acid—migraine	0.000165	0.00219	CcSEcCtD
Dabrafenib—Stomatitis—Gabapentin—migraine	0.000165	0.00219	CcSEcCtD
Dabrafenib—Urinary tract infection—Gabapentin—migraine	0.000165	0.00218	CcSEcCtD
Dabrafenib—Chills—Valproic Acid—migraine	0.000165	0.00218	CcSEcCtD
Dabrafenib—RAF1—brain—migraine	0.000164	0.0177	CbGeAlD
Dabrafenib—Arrhythmia—Valproic Acid—migraine	0.000164	0.00217	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Propranolol—migraine	0.000164	0.00216	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Topiramate—migraine	0.000163	0.00216	CcSEcCtD
Dabrafenib—Dizziness—Amitriptyline—migraine	0.000162	0.00215	CcSEcCtD
Dabrafenib—ABCG2—Fluoropyrimidine Activity—MTHFR—migraine	0.000162	0.00672	CbGpPWpGaD
Dabrafenib—Alopecia—Valproic Acid—migraine	0.000162	0.00215	CcSEcCtD
Dabrafenib—Haematuria—Gabapentin—migraine	0.000162	0.00214	CcSEcCtD
Dabrafenib—Oedema peripheral—Timolol—migraine	0.000161	0.00213	CcSEcCtD
Dabrafenib—Mental disorder—Valproic Acid—migraine	0.000161	0.00213	CcSEcCtD
Dabrafenib—Connective tissue disorder—Timolol—migraine	0.000161	0.00213	CcSEcCtD
Dabrafenib—Epistaxis—Gabapentin—migraine	0.00016	0.00212	CcSEcCtD
Dabrafenib—Malnutrition—Valproic Acid—migraine	0.00016	0.00212	CcSEcCtD
Dabrafenib—SLC22A6—brain—migraine	0.00016	0.0172	CbGeAlD
Dabrafenib—Fatigue—Verapamil—migraine	0.000159	0.0021	CcSEcCtD
Dabrafenib—Body temperature increased—Propranolol—migraine	0.000158	0.00209	CcSEcCtD
Dabrafenib—Abdominal pain—Propranolol—migraine	0.000158	0.00209	CcSEcCtD
Dabrafenib—Constipation—Verapamil—migraine	0.000157	0.00208	CcSEcCtD
Dabrafenib—Pancreatitis—Topiramate—migraine	0.000157	0.00208	CcSEcCtD
Dabrafenib—RAF1—Nongenotropic Androgen signaling—FOS—migraine	0.000157	0.00649	CbGpPWpGaD
Dabrafenib—Vomiting—Amitriptyline—migraine	0.000156	0.00207	CcSEcCtD
Dabrafenib—Rash—Amitriptyline—migraine	0.000155	0.00205	CcSEcCtD
Dabrafenib—Dermatitis—Amitriptyline—migraine	0.000155	0.00205	CcSEcCtD
Dabrafenib—Back pain—Valproic Acid—migraine	0.000155	0.00205	CcSEcCtD
Dabrafenib—Headache—Amitriptyline—migraine	0.000154	0.00204	CcSEcCtD
Dabrafenib—Muscle spasms—Valproic Acid—migraine	0.000154	0.00203	CcSEcCtD
Dabrafenib—Abdominal discomfort—Topiramate—migraine	0.000153	0.00203	CcSEcCtD
Dabrafenib—ABCB1—blood vessel—migraine	0.000153	0.0165	CbGeAlD
Dabrafenib—Eye disorder—Timolol—migraine	0.000153	0.00202	CcSEcCtD
Dabrafenib—Haemorrhage—Gabapentin—migraine	0.000152	0.00201	CcSEcCtD
Dabrafenib—RAF1—PDGFR-beta signaling pathway—LRP1—migraine	0.000152	0.0063	CbGpPWpGaD
Dabrafenib—Vision blurred—Valproic Acid—migraine	0.000151	0.00199	CcSEcCtD
Dabrafenib—Urinary tract disorder—Gabapentin—migraine	0.00015	0.00199	CcSEcCtD
Dabrafenib—Oedema peripheral—Gabapentin—migraine	0.00015	0.00198	CcSEcCtD
Dabrafenib—LIMK1—Caspase Cascade in Apoptosis—TNF—migraine	0.00015	0.00619	CbGpPWpGaD
Dabrafenib—Neutropenia—Topiramate—migraine	0.00015	0.00198	CcSEcCtD
Dabrafenib—Connective tissue disorder—Gabapentin—migraine	0.00015	0.00198	CcSEcCtD
Dabrafenib—Urethral disorder—Gabapentin—migraine	0.000149	0.00197	CcSEcCtD
Dabrafenib—Angiopathy—Timolol—migraine	0.000148	0.00196	CcSEcCtD
Dabrafenib—Anaemia—Valproic Acid—migraine	0.000148	0.00195	CcSEcCtD
Dabrafenib—Immune system disorder—Timolol—migraine	0.000148	0.00195	CcSEcCtD
Dabrafenib—BRAF—Neuronal System—CACNA1A—migraine	0.000147	0.0061	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Propranolol—migraine	0.000147	0.00195	CcSEcCtD
Dabrafenib—Mediastinal disorder—Timolol—migraine	0.000147	0.00195	CcSEcCtD
Dabrafenib—Arrhythmia—Timolol—migraine	0.000146	0.00193	CcSEcCtD
Dabrafenib—Nausea—Amitriptyline—migraine	0.000146	0.00193	CcSEcCtD
Dabrafenib—RAF1—Signaling of Hepatocyte Growth Factor Receptor—FOS—migraine	0.000146	0.00603	CbGpPWpGaD
Dabrafenib—RAF1—Trk receptor signaling mediated by the MAPK pathway—FOS—migraine	0.000146	0.00603	CbGpPWpGaD
Dabrafenib—Alopecia—Timolol—migraine	0.000144	0.00191	CcSEcCtD
Dabrafenib—Hyperglycaemia—Topiramate—migraine	0.000144	0.00191	CcSEcCtD
Dabrafenib—Asthenia—Propranolol—migraine	0.000143	0.0019	CcSEcCtD
Dabrafenib—Mental disorder—Timolol—migraine	0.000143	0.00189	CcSEcCtD
Dabrafenib—Leukopenia—Valproic Acid—migraine	0.000143	0.00189	CcSEcCtD
Dabrafenib—Infestation NOS—Topiramate—migraine	0.000143	0.00189	CcSEcCtD
Dabrafenib—Infestation—Topiramate—migraine	0.000143	0.00189	CcSEcCtD
Dabrafenib—Erythema—Timolol—migraine	0.000142	0.00188	CcSEcCtD
Dabrafenib—Malnutrition—Timolol—migraine	0.000142	0.00188	CcSEcCtD
Dabrafenib—Eye disorder—Gabapentin—migraine	0.000142	0.00188	CcSEcCtD
Dabrafenib—RAF1—SHP2 signaling—BDNF—migraine	0.000141	0.00582	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—TRPM8—migraine	0.00014	0.00581	CbGpPWpGaD
Dabrafenib—Renal failure—Topiramate—migraine	0.00014	0.00186	CcSEcCtD
Dabrafenib—Cough—Valproic Acid—migraine	0.000139	0.00185	CcSEcCtD
Dabrafenib—Stomatitis—Topiramate—migraine	0.000139	0.00184	CcSEcCtD
Dabrafenib—Urinary tract infection—Topiramate—migraine	0.000139	0.00183	CcSEcCtD
Dabrafenib—Hypertension—Valproic Acid—migraine	0.000138	0.00183	CcSEcCtD
Dabrafenib—Immune system disorder—Gabapentin—migraine	0.000137	0.00182	CcSEcCtD
Dabrafenib—Mediastinal disorder—Gabapentin—migraine	0.000137	0.00182	CcSEcCtD
Dabrafenib—Diarrhoea—Propranolol—migraine	0.000137	0.00181	CcSEcCtD
Dabrafenib—Chills—Gabapentin—migraine	0.000137	0.00181	CcSEcCtD
Dabrafenib—RAF1—GMCSF-mediated signaling events—FOS—migraine	0.000136	0.00563	CbGpPWpGaD
Dabrafenib—Myalgia—Valproic Acid—migraine	0.000136	0.0018	CcSEcCtD
Dabrafenib—Arthralgia—Valproic Acid—migraine	0.000136	0.0018	CcSEcCtD
Dabrafenib—Haematuria—Topiramate—migraine	0.000136	0.0018	CcSEcCtD
Dabrafenib—Hypersensitivity—Verapamil—migraine	0.000136	0.00179	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—migraine	0.000135	0.00179	CcSEcCtD
Dabrafenib—Epistaxis—Topiramate—migraine	0.000135	0.00178	CcSEcCtD
Dabrafenib—Alopecia—Gabapentin—migraine	0.000134	0.00178	CcSEcCtD
Dabrafenib—Vision blurred—Timolol—migraine	0.000134	0.00177	CcSEcCtD
Dabrafenib—Mental disorder—Gabapentin—migraine	0.000133	0.00176	CcSEcCtD
Dabrafenib—RAF1—Transmission across Chemical Synapses—CACNA1A—migraine	0.000133	0.00551	CbGpPWpGaD
Dabrafenib—Dry mouth—Valproic Acid—migraine	0.000133	0.00176	CcSEcCtD
Dabrafenib—Erythema—Gabapentin—migraine	0.000132	0.00175	CcSEcCtD
Dabrafenib—Malnutrition—Gabapentin—migraine	0.000132	0.00175	CcSEcCtD
Dabrafenib—Dizziness—Propranolol—migraine	0.000132	0.00175	CcSEcCtD
Dabrafenib—Asthenia—Verapamil—migraine	0.000132	0.00175	CcSEcCtD
Dabrafenib—SLC22A8—head—migraine	0.000132	0.0142	CbGeAlD
Dabrafenib—RAF1—PDGF Pathway—FOS—migraine	0.00013	0.0054	CbGpPWpGaD
Dabrafenib—Oedema—Valproic Acid—migraine	0.00013	0.00173	CcSEcCtD
Dabrafenib—Pruritus—Verapamil—migraine	0.00013	0.00172	CcSEcCtD
Dabrafenib—Infection—Valproic Acid—migraine	0.00013	0.00171	CcSEcCtD
Dabrafenib—Haemoglobin—Topiramate—migraine	0.000129	0.0017	CcSEcCtD
Dabrafenib—Back pain—Gabapentin—migraine	0.000128	0.0017	CcSEcCtD
Dabrafenib—Haemorrhage—Topiramate—migraine	0.000128	0.00169	CcSEcCtD
Dabrafenib—Nervous system disorder—Valproic Acid—migraine	0.000128	0.00169	CcSEcCtD
Dabrafenib—RAF1—IL-5 Signaling Pathway—FOS—migraine	0.000128	0.00529	CbGpPWpGaD
Dabrafenib—Thrombocytopenia—Valproic Acid—migraine	0.000128	0.00169	CcSEcCtD
Dabrafenib—Muscle spasms—Gabapentin—migraine	0.000127	0.00169	CcSEcCtD
Dabrafenib—Vomiting—Propranolol—migraine	0.000127	0.00168	CcSEcCtD
Dabrafenib—RAF1—Aryl Hydrocarbon Receptor—ESR1—migraine	0.000127	0.00525	CbGpPWpGaD
Dabrafenib—Skin disorder—Valproic Acid—migraine	0.000127	0.00168	CcSEcCtD
Dabrafenib—Urinary tract disorder—Topiramate—migraine	0.000126	0.00167	CcSEcCtD
Dabrafenib—Oedema peripheral—Topiramate—migraine	0.000126	0.00167	CcSEcCtD
Dabrafenib—Hyperhidrosis—Valproic Acid—migraine	0.000126	0.00167	CcSEcCtD
Dabrafenib—Rash—Propranolol—migraine	0.000126	0.00167	CcSEcCtD
Dabrafenib—Dermatitis—Propranolol—migraine	0.000126	0.00167	CcSEcCtD
Dabrafenib—Diarrhoea—Verapamil—migraine	0.000126	0.00167	CcSEcCtD
Dabrafenib—Connective tissue disorder—Topiramate—migraine	0.000126	0.00167	CcSEcCtD
Dabrafenib—Urethral disorder—Topiramate—migraine	0.000126	0.00166	CcSEcCtD
Dabrafenib—RAF1—ErbB2/ErbB3 signaling events—FOS—migraine	0.000125	0.00519	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—SCN1A—migraine	0.000125	0.00518	CbGpPWpGaD
Dabrafenib—SLC22A8—nervous system—migraine	0.000125	0.0135	CbGeAlD
Dabrafenib—Vision blurred—Gabapentin—migraine	0.000125	0.00165	CcSEcCtD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—TRPM8—migraine	0.000124	0.00514	CbGpPWpGaD
Dabrafenib—Cough—Timolol—migraine	0.000124	0.00164	CcSEcCtD
Dabrafenib—BRAF—Downstream signaling in naïve CD8+ T cells—FOS—migraine	0.000124	0.00512	CbGpPWpGaD
Dabrafenib—BRAF—TSH signaling pathway—FOS—migraine	0.000124	0.00512	CbGpPWpGaD
Dabrafenib—RAF1—IL-2 Signaling Pathway—FOS—migraine	0.000123	0.00509	CbGpPWpGaD
Dabrafenib—Hypertension—Timolol—migraine	0.000123	0.00163	CcSEcCtD
Dabrafenib—Anaemia—Gabapentin—migraine	0.000122	0.00162	CcSEcCtD
Dabrafenib—Hypotension—Valproic Acid—migraine	0.000122	0.00161	CcSEcCtD
Dabrafenib—Dizziness—Verapamil—migraine	0.000122	0.00161	CcSEcCtD
Dabrafenib—Arthralgia—Timolol—migraine	0.000121	0.0016	CcSEcCtD
Dabrafenib—Myalgia—Timolol—migraine	0.000121	0.0016	CcSEcCtD
Dabrafenib—RAF1—FCERI mediated MAPK activation—FOS—migraine	0.000121	0.00499	CbGpPWpGaD
Dabrafenib—SLC22A8—central nervous system—migraine	0.00012	0.013	CbGeAlD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Timolol—migraine	0.00012	0.00159	CcSEcCtD
Dabrafenib—Eye disorder—Topiramate—migraine	0.00012	0.00158	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Valproic Acid—migraine	0.000119	0.00157	CcSEcCtD
Dabrafenib—Nausea—Propranolol—migraine	0.000119	0.00157	CcSEcCtD
Dabrafenib—Leukopenia—Gabapentin—migraine	0.000119	0.00157	CcSEcCtD
Dabrafenib—Dry mouth—Timolol—migraine	0.000118	0.00157	CcSEcCtD
Dabrafenib—Insomnia—Valproic Acid—migraine	0.000118	0.00156	CcSEcCtD
Dabrafenib—Vomiting—Verapamil—migraine	0.000117	0.00155	CcSEcCtD
Dabrafenib—Angiopathy—Topiramate—migraine	0.000116	0.00154	CcSEcCtD
Dabrafenib—Oedema—Timolol—migraine	0.000116	0.00154	CcSEcCtD
Dabrafenib—Rash—Verapamil—migraine	0.000116	0.00154	CcSEcCtD
Dabrafenib—Dermatitis—Verapamil—migraine	0.000116	0.00153	CcSEcCtD
Dabrafenib—Immune system disorder—Topiramate—migraine	0.000116	0.00153	CcSEcCtD
Dabrafenib—Cough—Gabapentin—migraine	0.000116	0.00153	CcSEcCtD
Dabrafenib—Mediastinal disorder—Topiramate—migraine	0.000115	0.00153	CcSEcCtD
Dabrafenib—Infection—Timolol—migraine	0.000115	0.00153	CcSEcCtD
Dabrafenib—Headache—Verapamil—migraine	0.000115	0.00153	CcSEcCtD
Dabrafenib—Chills—Topiramate—migraine	0.000115	0.00152	CcSEcCtD
Dabrafenib—Hypertension—Gabapentin—migraine	0.000114	0.00151	CcSEcCtD
Dabrafenib—Nervous system disorder—Timolol—migraine	0.000114	0.00151	CcSEcCtD
Dabrafenib—Decreased appetite—Valproic Acid—migraine	0.000113	0.0015	CcSEcCtD
Dabrafenib—Alopecia—Topiramate—migraine	0.000113	0.0015	CcSEcCtD
Dabrafenib—Arthralgia—Gabapentin—migraine	0.000113	0.00149	CcSEcCtD
Dabrafenib—Myalgia—Gabapentin—migraine	0.000113	0.00149	CcSEcCtD
Dabrafenib—Skin disorder—Timolol—migraine	0.000113	0.00149	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Valproic Acid—migraine	0.000113	0.00149	CcSEcCtD
Dabrafenib—Fatigue—Valproic Acid—migraine	0.000112	0.00149	CcSEcCtD
Dabrafenib—Hyperhidrosis—Timolol—migraine	0.000112	0.00149	CcSEcCtD
Dabrafenib—Mental disorder—Topiramate—migraine	0.000112	0.00148	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—migraine	0.000112	0.00148	CcSEcCtD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2B—migraine	0.000112	0.00463	CbGpPWpGaD
Dabrafenib—Constipation—Valproic Acid—migraine	0.000112	0.00148	CcSEcCtD
Dabrafenib—Malnutrition—Topiramate—migraine	0.000111	0.00148	CcSEcCtD
Dabrafenib—Erythema—Topiramate—migraine	0.000111	0.00148	CcSEcCtD
Dabrafenib—Dry mouth—Gabapentin—migraine	0.00011	0.00146	CcSEcCtD
Dabrafenib—Nausea—Verapamil—migraine	0.000109	0.00145	CcSEcCtD
Dabrafenib—RAF1—IL-3 Signaling Pathway—FOS—migraine	0.000109	0.0045	CbGpPWpGaD
Dabrafenib—Hypotension—Timolol—migraine	0.000108	0.00144	CcSEcCtD
Dabrafenib—Oedema—Gabapentin—migraine	0.000108	0.00143	CcSEcCtD
Dabrafenib—Back pain—Topiramate—migraine	0.000108	0.00143	CcSEcCtD
Dabrafenib—Infection—Gabapentin—migraine	0.000107	0.00142	CcSEcCtD
Dabrafenib—Muscle spasms—Topiramate—migraine	0.000107	0.00142	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Valproic Acid—migraine	0.000107	0.00141	CcSEcCtD
Dabrafenib—RAF1—Axon guidance—SCN2A—migraine	0.000106	0.00441	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—ATP1A3—migraine	0.000106	0.0044	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—ATP1A2—migraine	0.000106	0.0044	CbGpPWpGaD
Dabrafenib—Nervous system disorder—Gabapentin—migraine	0.000106	0.0014	CcSEcCtD
Dabrafenib—Thrombocytopenia—Gabapentin—migraine	0.000106	0.0014	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Timolol—migraine	0.000106	0.0014	CcSEcCtD
Dabrafenib—Vision blurred—Topiramate—migraine	0.000105	0.00139	CcSEcCtD
Dabrafenib—Skin disorder—Gabapentin—migraine	0.000105	0.00139	CcSEcCtD
Dabrafenib—Insomnia—Timolol—migraine	0.000105	0.00139	CcSEcCtD
Dabrafenib—Hyperhidrosis—Gabapentin—migraine	0.000105	0.00138	CcSEcCtD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—TRPM8—migraine	0.000104	0.00429	CbGpPWpGaD
Dabrafenib—Abdominal pain—Valproic Acid—migraine	0.000103	0.00136	CcSEcCtD
Dabrafenib—Body temperature increased—Valproic Acid—migraine	0.000103	0.00136	CcSEcCtD
Dabrafenib—Anaemia—Topiramate—migraine	0.000103	0.00136	CcSEcCtD
Dabrafenib—RAF1—Neuronal System—CACNA1A—migraine	0.000102	0.00422	CbGpPWpGaD
Dabrafenib—Hypotension—Gabapentin—migraine	0.000101	0.00134	CcSEcCtD
Dabrafenib—Decreased appetite—Timolol—migraine	0.000101	0.00134	CcSEcCtD
Dabrafenib—RAF1—IL2-mediated signaling events—FOS—migraine	0.000101	0.00416	CbGpPWpGaD
Dabrafenib—Gastrointestinal disorder—Timolol—migraine	0.0001	0.00133	CcSEcCtD
Dabrafenib—Fatigue—Timolol—migraine	0.0001	0.00132	CcSEcCtD
Dabrafenib—RAF1—Transmembrane transport of small molecules—TRPM8—migraine	0.0001	0.00414	CbGpPWpGaD
Dabrafenib—Leukopenia—Topiramate—migraine	9.98e-05	0.00132	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Gabapentin—migraine	9.85e-05	0.0013	CcSEcCtD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—TGFBR2—migraine	9.81e-05	0.00406	CbGpPWpGaD
Dabrafenib—Insomnia—Gabapentin—migraine	9.78e-05	0.00129	CcSEcCtD
Dabrafenib—Cough—Topiramate—migraine	9.73e-05	0.00129	CcSEcCtD
Dabrafenib—Hypertension—Topiramate—migraine	9.62e-05	0.00127	CcSEcCtD
Dabrafenib—Hypersensitivity—Valproic Acid—migraine	9.61e-05	0.00127	CcSEcCtD
Dabrafenib—SLC22A8—brain—migraine	9.56e-05	0.0103	CbGeAlD
Dabrafenib—Gastrointestinal pain—Timolol—migraine	9.49e-05	0.00126	CcSEcCtD
Dabrafenib—BRAF—Corticotropin-releasing hormone—FOS—migraine	9.49e-05	0.00393	CbGpPWpGaD
Dabrafenib—Arthralgia—Topiramate—migraine	9.49e-05	0.00126	CcSEcCtD
Dabrafenib—Myalgia—Topiramate—migraine	9.49e-05	0.00126	CcSEcCtD
Dabrafenib—ABCB1—trigeminal ganglion—migraine	9.47e-05	0.0102	CbGeAlD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—TRPM8—migraine	9.43e-05	0.0039	CbGpPWpGaD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—migraine	9.42e-05	0.00125	CcSEcCtD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—ATP1A3—migraine	9.41e-05	0.00389	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—ATP1A2—migraine	9.41e-05	0.00389	CbGpPWpGaD
Dabrafenib—Decreased appetite—Gabapentin—migraine	9.4e-05	0.00124	CcSEcCtD
Dabrafenib—RAF1—Kit receptor signaling pathway—FOS—migraine	9.37e-05	0.00388	CbGpPWpGaD
Dabrafenib—Asthenia—Valproic Acid—migraine	9.36e-05	0.00124	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Gabapentin—migraine	9.33e-05	0.00124	CcSEcCtD
Dabrafenib—Fatigue—Gabapentin—migraine	9.32e-05	0.00123	CcSEcCtD
Dabrafenib—Dry mouth—Topiramate—migraine	9.28e-05	0.00123	CcSEcCtD
Dabrafenib—Constipation—Gabapentin—migraine	9.25e-05	0.00122	CcSEcCtD
Dabrafenib—Pruritus—Valproic Acid—migraine	9.23e-05	0.00122	CcSEcCtD
Dabrafenib—Abdominal pain—Timolol—migraine	9.18e-05	0.00121	CcSEcCtD
Dabrafenib—Body temperature increased—Timolol—migraine	9.18e-05	0.00121	CcSEcCtD
Dabrafenib—RAF1—Signaling by ERBB4—PGR—migraine	9.13e-05	0.00378	CbGpPWpGaD
Dabrafenib—RAF1—Fc-epsilon receptor I signaling in mast cells—FOS—migraine	9.12e-05	0.00378	CbGpPWpGaD
Dabrafenib—Oedema—Topiramate—migraine	9.1e-05	0.0012	CcSEcCtD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—HTR3A—migraine	9.04e-05	0.00374	CbGpPWpGaD
Dabrafenib—Infection—Topiramate—migraine	9.04e-05	0.0012	CcSEcCtD
Dabrafenib—BRAF—MAPK Signaling Pathway—TGFBR2—migraine	9.01e-05	0.00373	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—SCN1A—migraine	8.93e-05	0.0037	CbGpPWpGaD
Dabrafenib—Diarrhoea—Valproic Acid—migraine	8.92e-05	0.00118	CcSEcCtD
Dabrafenib—Nervous system disorder—Topiramate—migraine	8.92e-05	0.00118	CcSEcCtD
Dabrafenib—Thrombocytopenia—Topiramate—migraine	8.91e-05	0.00118	CcSEcCtD
Dabrafenib—RAF1—Endothelins—FOS—migraine	8.89e-05	0.00368	CbGpPWpGaD
Dabrafenib—Gastrointestinal pain—Gabapentin—migraine	8.84e-05	0.00117	CcSEcCtD
Dabrafenib—Skin disorder—Topiramate—migraine	8.84e-05	0.00117	CcSEcCtD
Dabrafenib—Hyperhidrosis—Topiramate—migraine	8.79e-05	0.00116	CcSEcCtD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—TRPM8—migraine	8.73e-05	0.00361	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—BDNF—migraine	8.67e-05	0.00359	CbGpPWpGaD
Dabrafenib—RAF1—Oncostatin M Signaling Pathway—FOS—migraine	8.67e-05	0.00359	CbGpPWpGaD
Dabrafenib—Dizziness—Valproic Acid—migraine	8.62e-05	0.00114	CcSEcCtD
Dabrafenib—RAF1—Leptin signaling pathway—ESR1—migraine	8.58e-05	0.00355	CbGpPWpGaD
Dabrafenib—RAF1—TSH signaling pathway—FOS—migraine	8.56e-05	0.00354	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—FOS—migraine	8.56e-05	0.00354	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Timolol—migraine	8.55e-05	0.00113	CcSEcCtD
Dabrafenib—Abdominal pain—Gabapentin—migraine	8.55e-05	0.00113	CcSEcCtD
Dabrafenib—Body temperature increased—Gabapentin—migraine	8.55e-05	0.00113	CcSEcCtD
Dabrafenib—BRAF—ErbB1 downstream signaling—FOS—migraine	8.54e-05	0.00353	CbGpPWpGaD
Dabrafenib—Hypotension—Topiramate—migraine	8.5e-05	0.00112	CcSEcCtD
Dabrafenib—RAF1—BCR signaling pathway—FOS—migraine	8.46e-05	0.0035	CbGpPWpGaD
Dabrafenib—ABCG2—cerebellum—migraine	8.38e-05	0.00903	CbGeAlD
Dabrafenib—Asthenia—Timolol—migraine	8.33e-05	0.0011	CcSEcCtD
Dabrafenib—Vomiting—Valproic Acid—migraine	8.29e-05	0.0011	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Topiramate—migraine	8.29e-05	0.0011	CcSEcCtD
Dabrafenib—Insomnia—Topiramate—migraine	8.23e-05	0.00109	CcSEcCtD
Dabrafenib—Rash—Valproic Acid—migraine	8.22e-05	0.00109	CcSEcCtD
Dabrafenib—Dermatitis—Valproic Acid—migraine	8.22e-05	0.00109	CcSEcCtD
Dabrafenib—Pruritus—Timolol—migraine	8.21e-05	0.00109	CcSEcCtD
Dabrafenib—Headache—Valproic Acid—migraine	8.17e-05	0.00108	CcSEcCtD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—HTR3A—migraine	8e-05	0.00331	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Gabapentin—migraine	7.97e-05	0.00105	CcSEcCtD
Dabrafenib—Diarrhoea—Timolol—migraine	7.94e-05	0.00105	CcSEcCtD
Dabrafenib—Decreased appetite—Topiramate—migraine	7.91e-05	0.00105	CcSEcCtD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—ATP1A3—migraine	7.85e-05	0.00325	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—ATP1A2—migraine	7.85e-05	0.00325	CbGpPWpGaD
Dabrafenib—Gastrointestinal disorder—Topiramate—migraine	7.85e-05	0.00104	CcSEcCtD
Dabrafenib—Fatigue—Topiramate—migraine	7.84e-05	0.00104	CcSEcCtD
Dabrafenib—Constipation—Topiramate—migraine	7.78e-05	0.00103	CcSEcCtD
Dabrafenib—Asthenia—Gabapentin—migraine	7.76e-05	0.00103	CcSEcCtD
Dabrafenib—Nausea—Valproic Acid—migraine	7.75e-05	0.00103	CcSEcCtD
Dabrafenib—Dizziness—Timolol—migraine	7.68e-05	0.00102	CcSEcCtD
Dabrafenib—Pruritus—Gabapentin—migraine	7.65e-05	0.00101	CcSEcCtD
Dabrafenib—RAF1—Developmental Biology—SCN2A—migraine	7.6e-05	0.00314	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—ATP1A2—migraine	7.59e-05	0.00314	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—ATP1A3—migraine	7.59e-05	0.00314	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—TGFBR2—migraine	7.56e-05	0.00313	CbGpPWpGaD
Dabrafenib—ABCG2—HIF-1-alpha transcription factor network—FOS—migraine	7.47e-05	0.00309	CbGpPWpGaD
Dabrafenib—Gastrointestinal pain—Topiramate—migraine	7.44e-05	0.000984	CcSEcCtD
Dabrafenib—BRAF—PDGFR-beta signaling pathway—FOS—migraine	7.43e-05	0.00307	CbGpPWpGaD
Dabrafenib—Diarrhoea—Gabapentin—migraine	7.4e-05	0.000979	CcSEcCtD
Dabrafenib—Vomiting—Timolol—migraine	7.38e-05	0.000977	CcSEcCtD
Dabrafenib—Rash—Timolol—migraine	7.32e-05	0.000969	CcSEcCtD
Dabrafenib—Dermatitis—Timolol—migraine	7.31e-05	0.000968	CcSEcCtD
Dabrafenib—Headache—Timolol—migraine	7.27e-05	0.000963	CcSEcCtD
Dabrafenib—Body temperature increased—Topiramate—migraine	7.19e-05	0.000952	CcSEcCtD
Dabrafenib—Abdominal pain—Topiramate—migraine	7.19e-05	0.000952	CcSEcCtD
Dabrafenib—Dizziness—Gabapentin—migraine	7.15e-05	0.000946	CcSEcCtD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—ATP1A2—migraine	7.15e-05	0.00296	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—ATP1A3—migraine	7.15e-05	0.00296	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—ESR1—migraine	7.08e-05	0.00293	CbGpPWpGaD
Dabrafenib—CYP2C8—brain—migraine	7e-05	0.00754	CbGeAlD
Dabrafenib—RAF1—Developmental Biology—MEF2D—migraine	6.95e-05	0.00288	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—NPS—migraine	6.92e-05	0.00286	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—migraine	6.92e-05	0.00286	CbGpPWpGaD
Dabrafenib—Nausea—Timolol—migraine	6.9e-05	0.000913	CcSEcCtD
Dabrafenib—Vomiting—Gabapentin—migraine	6.87e-05	0.00091	CcSEcCtD
Dabrafenib—ABCB1—cardiovascular system—migraine	6.84e-05	0.00737	CbGeAlD
Dabrafenib—Rash—Gabapentin—migraine	6.82e-05	0.000902	CcSEcCtD
Dabrafenib—Dermatitis—Gabapentin—migraine	6.81e-05	0.000901	CcSEcCtD
Dabrafenib—ABCG2—brain—migraine	6.8e-05	0.00734	CbGeAlD
Dabrafenib—RAF1—BDNF signaling pathway—BDNF—migraine	6.79e-05	0.00281	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2C—migraine	6.79e-05	0.00281	CbGpPWpGaD
Dabrafenib—Headache—Gabapentin—migraine	6.77e-05	0.000896	CcSEcCtD
Dabrafenib—Hypersensitivity—Topiramate—migraine	6.7e-05	0.000887	CcSEcCtD
Dabrafenib—RAF1—TCR Signaling Pathway—FOS—migraine	6.68e-05	0.00277	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—HTR3A—migraine	6.68e-05	0.00276	CbGpPWpGaD
Dabrafenib—BRAF—Downstream signaling in naïve CD8+ T cells—TNF—migraine	6.65e-05	0.00275	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—ATP1A3—migraine	6.62e-05	0.00274	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—ATP1A2—migraine	6.62e-05	0.00274	CbGpPWpGaD
Dabrafenib—RAF1—TWEAK Signaling Pathway—TNF—migraine	6.61e-05	0.00274	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRA—migraine	6.6e-05	0.00273	CbGpPWpGaD
Dabrafenib—RAF1—Corticotropin-releasing hormone—FOS—migraine	6.57e-05	0.00272	CbGpPWpGaD
Dabrafenib—Asthenia—Topiramate—migraine	6.53e-05	0.000864	CcSEcCtD
Dabrafenib—RAF1—Transmembrane transport of small molecules—HTR3A—migraine	6.45e-05	0.00267	CbGpPWpGaD
Dabrafenib—Pruritus—Topiramate—migraine	6.44e-05	0.000852	CcSEcCtD
Dabrafenib—Nausea—Gabapentin—migraine	6.42e-05	0.00085	CcSEcCtD
Dabrafenib—RAF1—MAPK Signaling Pathway—TGFBR2—migraine	6.23e-05	0.00258	CbGpPWpGaD
Dabrafenib—Diarrhoea—Topiramate—migraine	6.22e-05	0.000824	CcSEcCtD
Dabrafenib—CYP3A4—nervous system—migraine	6.2e-05	0.00669	CbGeAlD
Dabrafenib—RAF1—Aryl Hydrocarbon Receptor—TNF—migraine	6.15e-05	0.00254	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—HTR3A—migraine	6.08e-05	0.00251	CbGpPWpGaD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—FOS—migraine	6.04e-05	0.0025	CbGpPWpGaD
Dabrafenib—Dizziness—Topiramate—migraine	6.02e-05	0.000796	CcSEcCtD
Dabrafenib—RAF1—MAPK Signaling Pathway—BDNF—migraine	6e-05	0.00248	CbGpPWpGaD
Dabrafenib—CYP3A4—central nervous system—migraine	5.97e-05	0.00644	CbGeAlD
Dabrafenib—RAF1—Ceramide signaling pathway—TNF—migraine	5.94e-05	0.00246	CbGpPWpGaD
Dabrafenib—RAF1—ErbB1 downstream signaling—FOS—migraine	5.91e-05	0.00244	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—FOS—migraine	5.86e-05	0.00243	CbGpPWpGaD
Dabrafenib—Vomiting—Topiramate—migraine	5.78e-05	0.000765	CcSEcCtD
Dabrafenib—Rash—Topiramate—migraine	5.74e-05	0.000759	CcSEcCtD
Dabrafenib—Dermatitis—Topiramate—migraine	5.73e-05	0.000758	CcSEcCtD
Dabrafenib—Headache—Topiramate—migraine	5.7e-05	0.000754	CcSEcCtD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—HTR3A—migraine	5.63e-05	0.00233	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—BDNF—migraine	5.42e-05	0.00224	CbGpPWpGaD
Dabrafenib—Nausea—Topiramate—migraine	5.4e-05	0.000715	CcSEcCtD
Dabrafenib—RAF1—Cardiac Hypertrophic Response—TNF—migraine	5.33e-05	0.0022	CbGpPWpGaD
Dabrafenib—RAF1—PDGFR-beta signaling pathway—FOS—migraine	5.14e-05	0.00213	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—FOS—migraine	4.92e-05	0.00204	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—ESR1—migraine	4.88e-05	0.00202	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—RAMP1—migraine	4.8e-05	0.00199	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CALCRL—migraine	4.8e-05	0.00199	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—TRPM8—migraine	4.72e-05	0.00195	CbGpPWpGaD
Dabrafenib—ABCB1—head—migraine	4.63e-05	0.00499	CbGeAlD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—TNF—migraine	4.6e-05	0.00191	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—FOS—migraine	4.59e-05	0.0019	CbGpPWpGaD
Dabrafenib—ABCB1—nervous system—migraine	4.39e-05	0.00473	CbGeAlD
Dabrafenib—LIMK1—Innate Immune System—FOS—migraine	4.37e-05	0.00181	CbGpPWpGaD
Dabrafenib—ABCB1—central nervous system—migraine	4.23e-05	0.00456	CbGeAlD
Dabrafenib—RAF1—Insulin Signaling—FOS—migraine	4.22e-05	0.00175	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—FOS—migraine	4.18e-05	0.00173	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—migraine	4.16e-05	0.00172	CbGpPWpGaD
Dabrafenib—ABCB1—cerebellum—migraine	4.13e-05	0.00445	CbGeAlD
Dabrafenib—BRAF—Signaling Pathways—RAMP1—migraine	4.1e-05	0.0017	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CALCRL—migraine	4.1e-05	0.0017	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—ESR1—migraine	4.06e-05	0.00168	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—FOS—migraine	4.06e-05	0.00168	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—FOS—migraine	4.04e-05	0.00167	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—FOS—migraine	3.89e-05	0.00161	CbGpPWpGaD
Dabrafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TNF—migraine	3.8e-05	0.00157	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CACNA1A—migraine	3.6e-05	0.00149	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ATP1A2—migraine	3.58e-05	0.00148	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ATP1A3—migraine	3.58e-05	0.00148	CbGpPWpGaD
Dabrafenib—RAF1—TNF alpha Signaling Pathway—TNF—migraine	3.53e-05	0.00146	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HTR1D—migraine	3.49e-05	0.00144	CbGpPWpGaD
Dabrafenib—BRAF—Disease—LRP1—migraine	3.48e-05	0.00144	CbGpPWpGaD
Dabrafenib—ABCB1—brain—migraine	3.35e-05	0.00362	CbGeAlD
Dabrafenib—RAF1—Signaling by GPCR—HTR2B—migraine	3.24e-05	0.00134	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TNF—migraine	3.15e-05	0.0013	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—HTR3A—migraine	3.04e-05	0.00126	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HTR1D—migraine	2.98e-05	0.00123	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RAMP1—migraine	2.83e-05	0.00117	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CALCRL—migraine	2.83e-05	0.00117	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HTR2B—migraine	2.77e-05	0.00115	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—TNF—migraine	2.66e-05	0.0011	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—migraine	2.55e-05	0.00106	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—FOS—migraine	2.54e-05	0.00105	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—LRP1—migraine	2.44e-05	0.00101	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CACNA1A—migraine	2.42e-05	0.001	CbGpPWpGaD
Dabrafenib—RAF1—Disease—LRP1—migraine	2.41e-05	0.000996	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CALCA—migraine	2.24e-05	0.000928	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CACNA1A—migraine	2.24e-05	0.000927	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TNF—migraine	2.18e-05	0.000902	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HTR1B—migraine	2.11e-05	0.000874	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR1D—migraine	2.06e-05	0.000852	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HTR1A—migraine	2.03e-05	0.000841	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—NPS—migraine	2e-05	0.000829	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—TAC1—migraine	2e-05	0.000829	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—migraine	1.97e-05	0.000814	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HTR2C—migraine	1.96e-05	0.000813	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—migraine	1.92e-05	0.000793	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR2B—migraine	1.91e-05	0.000792	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EDNRA—migraine	1.91e-05	0.00079	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TNF—migraine	1.88e-05	0.000778	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOTCH4—migraine	1.87e-05	0.000774	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CALCA—migraine	1.84e-05	0.000761	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFBR2—migraine	1.81e-05	0.000747	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HTR1B—migraine	1.8e-05	0.000746	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HTR1A—migraine	1.74e-05	0.000718	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HTR7—migraine	1.72e-05	0.000712	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PGR—migraine	1.71e-05	0.000708	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NPS—migraine	1.71e-05	0.000708	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TAC1—migraine	1.71e-05	0.000708	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—LRP1—migraine	1.69e-05	0.000698	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HTR2C—migraine	1.68e-05	0.000694	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EDNRA—migraine	1.63e-05	0.000675	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOTCH3—migraine	1.59e-05	0.000658	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CALCA—migraine	1.57e-05	0.00065	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CALCA—migraine	1.55e-05	0.000642	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FOS—migraine	1.51e-05	0.000626	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HTR7—migraine	1.47e-05	0.000608	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MTHFR—migraine	1.47e-05	0.000607	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CACNA1A—migraine	1.39e-05	0.000575	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOTCH4—migraine	1.29e-05	0.000535	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFBR2—migraine	1.26e-05	0.000523	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFBR2—migraine	1.25e-05	0.000517	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR1B—migraine	1.25e-05	0.000516	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CACNA1A—migraine	1.21e-05	0.000501	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HTR2A—migraine	1.2e-05	0.000498	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR1A—migraine	1.2e-05	0.000497	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—MTHFR—migraine	1.19e-05	0.000493	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TAC1—migraine	1.18e-05	0.00049	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NPS—migraine	1.18e-05	0.00049	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PGR—migraine	1.18e-05	0.00049	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR2C—migraine	1.16e-05	0.00048	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EDNRA—migraine	1.13e-05	0.000467	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOTCH3—migraine	1.1e-05	0.000455	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CALCA—migraine	1.09e-05	0.00045	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HTR2A—migraine	1.03e-05	0.000426	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR7—migraine	1.02e-05	0.00042	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTHFR—migraine	1.01e-05	0.00042	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—migraine	9.28e-06	0.000384	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—migraine	9.2e-06	0.000381	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ESR1—migraine	9.13e-06	0.000378	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FOS—migraine	8.8e-06	0.000364	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFBR2—migraine	8.75e-06	0.000362	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MTHFR—migraine	8e-06	0.000331	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CACNA1A—migraine	7.46e-06	0.000309	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MTHFR—migraine	7.41e-06	0.000307	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR2A—migraine	7.12e-06	0.000294	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ESR1—migraine	6.32e-06	0.000261	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—migraine	4.6e-06	0.00019	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—migraine	4.01e-06	0.000166	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—migraine	2.47e-06	0.000102	CbGpPWpGaD
